TY - JOUR T1 - Mortality from COVID-19 in 12 countries and 6 states of the United States JF - medRxiv DO - 10.1101/2020.04.17.20069161 SP - 2020.04.17.20069161 AU - Patrick Brown AU - Kamal Rai AU - Carlo La Vecchia AU - Peter S Rodriguez AU - Kathleen Qu AU - Mathew G Brown AU - Hwashin Hyun Shin AU - Xuyang Tang AU - Leslie Newcombe AU - Wilson Suraweera AU - Craig Schultz AU - Isaac Bogoch AU - Hellen Gelband AU - Nico Nagelkerke AU - Prabhat Jha Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/22/2020.04.17.20069161.abstract N2 - Importance Reliable estimates of COVID-19 mortality are crucial to aid control strategies and to assess the effectiveness of interventions.Objective Project COVID-19 mortality trends to October 1, 2020, in 12 countries or regions that constitute >90% of the global COVID-19 deaths reported as of April 12, 2020.Design, Setting, and Participants The Global COVID-19 Assessment of Mortality (GCAM) is an open, transparent, and continuously updated (www.cghr.org/covid) statistical model that combines actual COVID-19 mortality counts with Bayesian inference to forecast COVID-19 deaths, the date of peak deaths, and the duration of excess mortality. The analyses covered a total of 700 million population above age 20 in 12 countries or regions: USA; Italy; Spain; France; UK; Iran; Belgium; a province of China (Hubei, which accounted for 90% of reported Chinese deaths); Germany; the Netherlands; Switzerland; and Canada; and six US states: New York, New Jersey, Michigan, Louisiana, California, and Washington.Results Forecasted deaths across the 12 current high-burden countries sum 167,000 to 593,000 (median 253,000). The trajectory of US deaths (49,000-249,000 deaths; median 86,000)—over half of which are expected in states beyond the initial six states analysed in this study—will have the greatest impact on the eventual total. Mortality ranges are 25,000-109,000 (median 46,000) in the UK; 23,000-31,000 (median 26,000) in Italy; 21,000-37,000 (median 26,000) in France and 21,000-32,000 (median 25,000) in Spain. Estimates are most precise for Hubei, China—where the epidemic curve is complete—and least precise in California, where it is ongoing. New York has the highest cumulative median mortality rate per million (1135), about 12-fold that of Germany. Mortality trajectories are notably flatter in Germany, California, and Washington State, each of which took physical distancing and testing strategies seriously. Using past country-specific mortality as a guide, GCAM predicts surge capacity needs, reaching more than twice existing capacity in a number of places., In every setting, the results might be sensitive to undercounts of COVID-19 deaths, which are already apparent.Conclusion and Relevance Mortality from COVID-19 will be substantial across many settings, even in the best case scenario. GCAM will provide continually updated and increasingly precise estimates as the pandemic progresses.The coronavirus disease (COVID-19) pandemic has already caused over 115,000 deaths, with global deaths doubling every week.1-3 Mortality is less biased than case reporting, which is affected by testing policies. However, the daily reporting of COVID-19 deaths is already known to undercount actual deaths, varying over time and place.4-6Reliable estimates of total COVID-19 mortality, the date of peak deaths, and of the duration of excess mortality are crucial to aid responses to the current and potential future pandemics. We have developed the Global COVID-19 Assessment of Mortality (GCAM), a statistical model to project COVID-19 mortality trends to October 1 2020 in 12 countries or regions that constitute >90% of the global COVID-19 deaths reported as of April 12th. We report also on six US states that account for 70% of the American totals to date (Supplementary Appendix).1 We quantify the COVID-19 mortality trajectory ranges in each setting. A semi-automated website (www.cghr.org/covid) provides daily updates. GCAM is open, transparent, and uses a reasonably simple method that employs publicly reported mortality data to make plausible projections. The method is designed to improve as more mortality data become available over longer time periods.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partly supported by the the Canadian Institutes of Health Research Foundation grant (FDN 154277) and Emergency COVID-19 Research Grant, and the Connaught Global Challenge program of the University of Toronto.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available on www.cghr.org/covid including the source code for the analyses. https://www.cghr.org/covid ER -